NYSE:HRC - Hill-Rom Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$92.76 -2.99 (-3.12 %)
(As of 12/10/2018 02:30 AM ET)
Previous Close$92.76
Today's Range$92.56 - $95.82
52-Week Range$78.16 - $99.81
Volume494,073 shs
Average Volume400,213 shs
Market Capitalization$6.24 billion
P/E Ratio19.53
Dividend Yield0.86%
Beta0.94
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as blood pressure, physical assessment, vital signs monitoring, diagnostic cardiopulmonary, diabetic retinopathy screening, and thermometry products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, and Monarch systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables; and operating room surgical safety and accessory products, which comprise scalpels and blades, light handle systems, skin markers, and other disposable products. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Receive HRC News and Ratings via Email

Sign-up to receive the latest news and ratings for HRC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:HRC
Previous SymbolNYSE:HB
CUSIP43147510
Phone312-819-7200

Debt

Debt-to-Equity Ratio1.11
Current Ratio1.74
Quick Ratio1.30

Price-To-Earnings

Trailing P/E Ratio19.53
Forward P/E Ratio18.08
P/E Growth1.29

Sales & Book Value

Annual Sales$2.47 billion
Price / Sales2.53
Cash Flow$7.9079 per share
Price / Cash Flow11.73
Book Value$24.34 per share
Price / Book3.81

Profitability

EPS (Most Recent Fiscal Year)$4.75
Net Income$252.40 million
Net Margins8.86%
Return on Equity21.10%
Return on Assets7.23%

Miscellaneous

Employees10,000
Outstanding Shares67,280,000
Market Cap$6.24 billion
OptionableOptionable

Hill-Rom (NYSE:HRC) Frequently Asked Questions

What is Hill-Rom's stock symbol?

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?

Hill-Rom declared a quarterly dividend on Thursday, November 8th. Stockholders of record on Friday, December 14th will be paid a dividend of $0.20 per share on Monday, December 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, December 13th. View Hill-Rom's Dividend History.

How were Hill-Rom's earnings last quarter?

Hill-Rom Holdings, Inc. (NYSE:HRC) issued its earnings results on Friday, November, 2nd. The medical technology company reported $1.63 EPS for the quarter, beating the Zacks' consensus estimate of $1.51 by $0.12. The medical technology company earned $759.20 million during the quarter, compared to analyst estimates of $750.90 million. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. Hill-Rom's revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.32 earnings per share. View Hill-Rom's Earnings History.

When is Hill-Rom's next earnings date?

Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, January 25th 2019. View Earnings Estimates for Hill-Rom.

What guidance has Hill-Rom issued on next quarter's earnings?

Hill-Rom issued an update on its FY19 earnings guidance on Friday, November, 2nd. The company provided EPS guidance of $5.08-5.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.08. The company issued revenue guidance of $2.88-2.90 billion (+1-2%), compared to the consensus revenue estimate of $2.93 billion.Hill-Rom also updated its FY 2019 guidance to $5.08-5.16 EPS.

What price target have analysts set for HRC?

8 equities research analysts have issued 1 year price objectives for Hill-Rom's stock. Their forecasts range from $85.00 to $115.00. On average, they expect Hill-Rom's stock price to reach $103.1250 in the next year. This suggests a possible upside of 11.2% from the stock's current price. View Analyst Price Targets for Hill-Rom.

What is the consensus analysts' recommendation for Hill-Rom?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.

Has Hill-Rom been receiving favorable news coverage?

Media headlines about HRC stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Hill-Rom earned a news impact score of 0.8 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.

Who are some of Hill-Rom's key competitors?

Who are Hill-Rom's key executives?

Hill-Rom's management team includes the folowing people:
  • Mr. Steven J. Strobel, Sr. VP & CFO (Age 60)
  • Ms. Deborah M. Rasin, Sr. VP, Chief Legal Officer & Sec. (Age 51)
  • Mr. Alton E. Shader, Sr. VP & Pres of Front Line Care (Age 45)
  • Mr. Carlos Alonso-Marum, Sr. VP & Pres of International (Age 59)
  • Mr. John P. Groetelaars, Pres, CEO & Director (Age 51)

Who are Hill-Rom's major shareholders?

Hill-Rom's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.24%), Vanguard Group Inc. (8.79%), FMR LLC (2.75%), Bank of Montreal Can (2.57%), Fisher Asset Management LLC (1.97%) and Renaissance Technologies LLC (1.73%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Andrew Macritchie, Deborah Rasin, John J Greisch, Mary Garrett and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.

Which institutional investors are selling Hill-Rom stock?

HRC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Prudential Financial Inc., Allianz Asset Management GmbH, First Trust Advisors LP, Neuberger Berman Group LLC, Fisher Asset Management LLC and WINTON GROUP Ltd. Company insiders that have sold Hill-Rom company stock in the last year include Alton Shader, Andreas G Frank, Deborah Rasin, John J Greisch and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.

Which institutional investors are buying Hill-Rom stock?

HRC stock was purchased by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Jennison Associates LLC, Select Equity Group L.P., Marshall Wace LLP, Morgan Stanley, Valeo Financial Advisors LLC, Man Group plc and Engineers Gate Manager LP. Company insiders that have bought Hill-Rom stock in the last two years include Andrew Macritchie and Mary Garrett. View Insider Buying and Selling for Hill-Rom.

How do I buy shares of Hill-Rom?

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hill-Rom's stock price today?

One share of HRC stock can currently be purchased for approximately $92.76.

How big of a company is Hill-Rom?

Hill-Rom has a market capitalization of $6.24 billion and generates $2.47 billion in revenue each year. The medical technology company earns $252.40 million in net income (profit) each year or $4.75 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.

What is Hill-Rom's official website?

The official website for Hill-Rom is http://www.hill-rom.com.

How can I contact Hill-Rom?

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]


MarketBeat Community Rating for Hill-Rom (NYSE HRC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  315 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  642
MarketBeat's community ratings are surveys of what our community members think about Hill-Rom and other stocks. Vote "Outperform" if you believe HRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel